Innate Pharma: abstract on IPH45 at the AACR congress

(CercleFinance.com) - Innate Pharma announces that an abstract presenting its preclinical active ingredient IPH45 has been selected for an oral presentation at the annual meeting of the AACR (American Association for Cancer Research), to be held from April 5 to 10 in San Diego, USA.


IPH45 is a novel antibody conjugate targeting nectin-4 -a cell membrane adhesion protein overexpressed in several solid tumors- and differentiated with a topoisomerase I inhibitor as a cytotoxic agent.

Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and has a favorable safety profile in preclinical studies", emphasizes Eric Vivier, Chief Scientific Officer of Innate Pharma.

Copyright (c) 2024 CercleFinance.com. All rights reserved.